COMMUNIQUÉS West-GlobeNewswire

First-of-its-kind Trojan Horse Cancer Treatment Approved for Clinical Trials
20/01/2026
Peptinovo Biopharma’s Targeted Cancer Drug Platform Moves to Human Trials in Australia ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering [...]
Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
20/01/2026
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell Engager (BRiTE), yields [...]
Comfort Keepers Ireland Highlights Urgent Need for Scaling Safe, Regulated Home Support
20/01/2026
Report Emphasises the Importance of Home Support in Alleviating Hospital Pressures and Supporting Aging Population Dublin, Ireland, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Comfort Keepers Ireland , a leading homecare provider [...]
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
20/01/2026
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances [...]
Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
20/01/2026
Company implements next growth stage following successful strategic and operational development Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, appointed interim CEO LAUPHEIM, Germany and MILFORD, Mass., Jan [...]
Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference
20/01/2026
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Orphai Therapeutics Inc. (“Orphai”) , a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant [...]
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
20/01/2026
CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced continued operational growth [...]
Vitalic Health, powered by HFMA, launches U.S. Healthcare Vitals Tracker to measure affordability, financial sustainability and health outcomes
20/01/2026
CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association’s Vitalic Health today released the U.S. Vitals Tracker, a first-of-its-kind tool that measures the health of U.S. healthcare. [...]
Next-Generation Healthcare Provider ONTO Health Names Dr. Roohi Jeelani Founder & CEO, Expands to Chicago and the Midwest
20/01/2026
ONTO Health is advancing a more comprehensive, human-centered approach to healthcare, supporting health and well-being across the lifespan Chicago, Jan. 20, 2026 (GLOBE NEWSWIRE) -- ONTO Health , a next-generation [...]
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
20/01/2026
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
New Research Reveals Key Quality of Life Insights in ADHD Management
20/01/2026
Qbtech research analyzing nearly 1,000 patients found a correlation between objective ADHD performance and meaningful changes in daily functioning and well-being HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Qbtech , a [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
20/01/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 20 janvier 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
CARBIOS : Bilan semestriel du contrat de liquidité confié à Natixis ODDO BHF et annonce de sa suspension
20/01/2026
Titre concerné : CARBIOS (code ISIN FR0011648716) Marché concerné : Euronext Growth Paris Clermont-Ferrand (France), le 20 janvier 2026 (18h00 CET). CARBIOS présente le bilan semestriel du contrat de liquidité conclu [...]
CARBIOS : half-year report on the liquidity contract entrusted to Natixis ODDO BHF and notice of suspension
20/01/2026
PRESS RELEASE Shares concerned: Carbios (ISIN code: FR0011648716) Market concerned: Euronext Growth Paris Clermont-Ferrand, France, January 20, 2026 (6:00 pm CET). CARBIOS today presents the half-year report on the [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
20/01/2026
Bilan semestriel du contrat de liquidité avec Invest Securities Nantes, le 20 janvier 2026, 18 heures – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]
Half-Year Report on Liquidity Contract with Invest Securities
20/01/2026
Half-Year Report on Liquidity Contract with Invest Securities NANTES, France - January 20, 2026, 6:00pm CET – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following [...]
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
20/01/2026
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
20/01/2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second [...]
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference
20/01/2026
Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the [...]

Pages